Idiopathic Membranous Nephropathy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Roche, MorphoSys, Cerium Pharmaceuticals

DelveInsight Business Research LLP

DelveInsight’s “Idiopathic Membranous Nephropathy (IMN) – Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of historical and forecasted epidemiology as well as market trends of IMN in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.

Key Highlights of the Idiopathic Membranous Nephropathy Market 

• The Key Companies working in the Idiopathic Membranous Nephropathy  market include Hoffmann-La Roche, MorphoSys, Cerium Pharmaceuticals, BeiGene, Reistone Biopharma, Eternity Bioscience, GlaxoSmithKline, ValenzaBio, ACELYRIN and many others.

• The Key Therapies working in the Idiopathic Membranous Nephropathy   market include GAZYVA , MOR202 , and many others.

Idiopathic Membranous Nephropathy Overview

Membranous Nephropathy (MN), also known as membranous glomerulonephritis (MGN), is a rare autoimmune disorder characterized by a pathological change in the glomerular basement membrane due to the deposition of subepithelial immune complexes. Membraneous Nephropathy causes protein increase in urine, abnormal kidney function, and swelling. It is also called membranous glomerulopathy. MN is a rare disease affecting the kidney glomerulus, specifically the podocytes, which control the kidney’s permeability to proteins. Albumin and higher molecular weight proteins are minimally filtered in a healthy individual. In contrast, in nephrotic syndrome, large amounts of proteins escape into the urine, decreasing serum albumin and developing generalized edema.

The most common symptom of MN is swelling, referred to as edema. This can range from mild to severe. Most people have some swelling, often the first symptom. In MN (as opposed to other diseases that cause protein in the urine and nephrotic syndrome), swelling is usually slow (over weeks to months), but it can sometimes come quickly. It typically starts in the feet, ankles, or legs but can occur anywhere in the body, including the abdomen, hands, arms, and face. It occurs due to fluid build-up in the body, specifically in different tissues.

Histologically, MN has been classified into primary and secondary types. Idiopathic or Primary MN is considered to be an antibody-mediated autoimmune disease, whereas secondary MN occurs in association with other diseases such as systemic lupus erythematosus (SLE), infections and malignancies, or exposure to toxins as well as certain medications such as non-steroidal anti-inflammatory drugs, TNF alpha-blockers, and other therapies.

Idiopathic Membranous Nephropathy Epidemiology Insights

• The total Idiopathic Membranous Nephropathy  cases in the US were approximately 29,000 in 2022 and are projected to increase during the forecast period (2023–2032).

• China contributed to the largest prevalent population of Idiopathic Membranous Nephropathy, acquiring ~82% of the 7MM and China in 2022. Whereas EU4 and the UK, and Japan accounted for around 5% of the total population share, each in 2022.

• In 2022, the US accounted for approximately 19,000 cases in the addressable pool of IMN.

• Among the EU4 countries, Germany accounted for the largest number of Idiopathic Membranous Nephropathy cases, followed by the UK, whereas France accounted for the lowest number of cases in 2022.

• DelveInsight estimates that around 23,000, 800, and 5,000 cases of PLA2R antigen, THSD7A antigen, and other antigens were observed in the US in 2022. The cases are projected to increase during the forecast period.

• In 2022, total IMN cases in Japan were approximately 16,000, estimated to increase during the forecast period (2023–2032).

Click here to learn more about the Idiopathic Membranous NephropathyMarket Landscape

The Report Covers the Idiopathic Membranous Nephropathy Epidemiology Segmented by:

• Idiopathic Membranous Nephropathy diagnosed cases 

• Idiopathic Membranous Nephropathy incident cases

• Idiopathic Membranous Nephropathy prevalent cases 

• Idiopathic Membranous Nephropathy treatment cases 

Idiopathic Membranous Nephropathy Market Outlook 

There is no cure for membranous nephropathy. With the patients having the condition, doctor’s focus on the treatment, generally, adopt a symptomatic approach, and try strengthening the patient’s immune system. Patients are started with supportive therapy regardless of underlying etiology as soon as the diagnosis is confirmed and continued for the course of the disease. Treatment includes careful BP control, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to minimize proteinuria and enhance chances of spontaneous remission, statins for hyperlipidemia, salt restriction, and diuretics to control edema, and a low protein diet allowing for replacement of urinary protein losses. In recent studies, alkylating agents alternating with corticosteroids demonstrated favorable outcomes in patients with MN. The 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines rate this treatment regimen as the first line. Because of the role of B cells in autoantibody production in membranous nephropathy combined with adverse effects of alkylating agents, corticosteroids, and calcineurin inhibitors, increasing amounts of observational data have emerged about the effectiveness of rituximab. However, a lack of randomized, controlled trials precluded consideration of rituximab as a first-line agent.

Key Companies Working in the Idiopathic Membranous Nephropathy Market

• Roche

• MorphoSys

• Cerium Pharmaceuticals

• BeiGene

And many others 

Idiopathic Membranous Nephropathy  Therapies Covered and Analyzed in the Report

• GAZYVA 

• MOR202 

And many others 

Learn more about the Key Companies and Emerging Therapies in the Idiopathic Membranous Nephropathy Market

Table of Contents 

1. Key Insights 

2. Idiopathic Membranous Nephropathy Introduction 

3. Executive Summary of Idiopathic Membranous Nephropathy             

4. Disease Background and Overview

5. Epidemiology and Patient Population

6. Idiopathic Membranous Nephropathy  Emerging Therapies

7. Idiopathic Membranous Nephropathy  Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Idiopathic Membranous Nephropathy  Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services